I. The Industry Has More Data Than Vision Biotechnology has become extraordinarily good at seeing the small. It can sequence a tumor, profile a transcriptome, quantify protein expression, monitor oxygen transfer, measure immune activation, model binding affinity, and predict structure at a level of resolution that would have seemed impossible a generation ago. It can […]
In the cadence of the Chinese calendar, 2026 marks the arrival of the Year of the Fire Horse — a rare alignment that emerges only once every sixty years. Fire signifies acceleration and transformation: decisive force applied with consequence. It illuminates pressure points, compresses timelines, and converts latent potential into forward movement. The Horse represents […]
2026 is the inflection point where biotechnology stops being priced on promise and starts being priced on conversion. This isn’t a change in sentiment. It’s a change in operating constraints. Capital, regulators, and operators now press the same question: can you keep truth intact as a programme moves from concept to scale—through handoffs, pressure, and […]
(A note on: biotech, techbio, food tech, and the new operating physics of “real companies”) Every cycle reaches a point where narrative stops clearing the bar. The change is not theatrical. It shows up as a shift in diligence questions—questions that are operational, specific, and hard to bluff. When the questions change, the valuation framework […]
Where Biotech Actually Fails: Scale Is Not an Extension of the Lab Biotech still tells itself that scale is a later problem. In biotech in 2026, that belief is no longer naive — it is actively dangerous. The lab works.The data looks good.The organism behaves.The molecule binds.The titer hits the slide. And somewhere between that […]
I. The Invisible Problem: Biomanufacturing Fails at the Edges Biomanufacturing does not fail in the clean, brightly lit parts of the process. It fails in the margins — the boundaries where one domain touches another and no single actor feels responsible for the distortion that happens there. Everyone in the industry believes they understand the […]
The defining question in biotechnology is shifting from discovery for its own sake to disciplined execution at scale. The center of gravity is moving from isolated breakthroughs to integrated systems where design, data, and production are inseparable. It’s no longer Can we build it?—it’s How fast can we validate, scale, and supply it? The advantage […]
We bring clarity to the vision within your company. In business, as in science, the most mythologized leap is the one from zero to one. It is the first spark, the improbable moment where an idea becomes reality, where nothing gives way to something. In biotechnology, this leap carries particular weight: a first molecule expressed, […]